Cocrystal Pharma, Inc. (COCP) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing broad-spectrum antiviral drug candidates for influenza, norovirus, coronavirus, and hepatitis C. This report covers the quarterly period ended September 30, 2025. The company operates as a single segment and is currently incurring losses while advancing its clinical programs.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2,049,000) | $(4,939,000) | $(6,405,000) | $(14,238,000) |
| Operating Expenses | $(2,089,000) | $(5,042,000) | $(6,538,000) | $(14,648,000) |
| Research & Development | $(954,000) | $(3,242,000) | $(3,436,000) | $(10,500,000) |
| General & Administrative | $(1,135,000) | $(1,800,000) | $(3,102,000) | $(4,148,000) |
| Cash Used in Operating Activities (YTD) | $(6,456,000) vs $(13,325,000) prior year | |||
| Cash and Restricted Cash (Sept 30, 2025) | $7,804,000 | |||
| Total Liabilities | $2,777,000 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 59% year-over-year for the nine-month period, driven primarily by the winding down of high-cost clinical trial phases for the Influenza (CC-42344) and Norovirus/Coronavirus (CDI-988) programs.
- Capital Raise: In Q3 2025, the company raised approximately $4.34 million through a registered direct offering and ATM sales, compared to no financing activity in the same period in 2024.
- ATM Termination: The company terminated sales under its At-The-Market (ATM) offering agreement on September 12, 2025, though the agreement remains in effect.
- Stock-Based Compensation: Stock-based compensation expense decreased significantly to $214,000 for the nine months ended Sept 30, 2025, compared to $558,000 in the prior year period.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. With approximately $7.8 million in cash, the company estimates resources are insufficient to fund operations beyond the next 12 months. Additional capital will be required to continue clinical development.
- Clinical Progress:
- Influenza (CC-42344): Completed Phase 2a human challenge study with favorable safety and tolerability results. Development continues for pandemic and seasonal influenza A.
- Norovirus/Coronavirus (CDI-988): Completed Phase 1 studies showing safety and tolerability up to 1,200 mg. Received FDA "Study May Proceed" letter for a Phase 1b challenge study expected to begin in H1 2026.
- Recent Financing: On October 28, 2025 (subsequent event), the company raised an additional $1.03 million from four insider investors. On October 27, 2025, the company received a $500,000 SBIR Phase I award from the NIH/NIAID.
- Risks: Primary risks include the inability to secure additional financing on acceptable terms, potential dilution to shareholders, and the failure of product candidates to receive regulatory approval or demonstrate efficacy in future trials.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.8 million cash balance against projected burn rates for the upcoming 12 months, given the "substantial doubt" disclosure.
- Dilution Impact: Assess the impact of the recent registered direct offering and subsequent insider offering, including the issuance of ~5.7 million warrants with an exercise price of $1.50.
- Clinical Milestones: Confirm the timeline and budget for the upcoming Phase 1b norovirus challenge study scheduled for H1 2026.
- ATM Status: Monitor for the filing of a new prospectus supplement if the company intends to resume sales under the ATM agreement.
- Related Party Transactions: Review lease agreements with entities controlled by Dr. Phillip Frost (director/principal stockholder) for terms and related party expense impacts.